venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

Venture Capital Concept on the Mechanism of Metal Gears.
venBio raised $394m for its third fund; its prior fund totaled $340m • Source: Shutterstock

Economic uncertainty tied to the ongoing COVID-19 pandemic did not keep the life science-focused venture capital firm venBio from being able to close its third fund, which totaled $394m. In fact, the fund was oversubscribed, surpassing venBio’s initial goal of $250m, with heavy interest from big pharma companies and other investors, according to managing partner Corey Goodman.

Goodman told Scrip that venBio and its investors began to discuss the possibility of a near-term economic downturn at least...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.